TCGA-22-5480-01A-01R-1635-07
— · cohortSQ1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSQ1
- subtype
- cohortSQ1
- age_years
- 66
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.570
- MYC_TARGETS_V1+0.490
- INTERFERON_GAMMA_RESPONSE+0.470
- MYC_TARGETS_V2+0.470
- G2M_CHECKPOINT+0.420
- E2F_TARGETS+0.410
- WNT_BETA_CATENIN_SIGNALING+0.410
- ALLOGRAFT_REJECTION+0.380
- HEDGEHOG_SIGNALING+0.310
- IL6_JAK_STAT3_SIGNALING+0.300
Top 10 suppressed
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.360
- COAGULATION-0.320
- MYOGENESIS-0.270
- XENOBIOTIC_METABOLISM-0.270
- CHOLESTEROL_HOMEOSTASIS-0.260
- BILE_ACID_METABOLISM-0.240
- FATTY_ACID_METABOLISM-0.220
- ADIPOGENESIS-0.200
- GLYCOLYSIS-0.190
- ANGIOGENESIS-0.180
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_H1ZS5FMZ | high-grade glioma | — | 0.846 |
| 2 | TCGA-85-7950-01A-11R-2187-07 | — | cohortSQ1 | 0.845 |
| 3 | TCGA-90-7767-01A-11R-2125-07 | — | cohortSQ1 | 0.838 |
| 4 | 3F932445-1D8F-4128-A8DA-F36EA9F6E745 | — | — | 0.833 |
| 5 | C3N-03093 | — | cohortA1 | 0.823 |
| 6 | SRR934757 | — | — | 0.819 |
| 7 | TCGA-96-A4JL-01A-11R-A24Z-07 | — | cohortSQ1 | 0.809 |
| 8 | SRR934775 | — | — | 0.793 |
| 9 | SRR934774 | — | — | 0.793 |
| 10 | SRR934806 | — | — | 0.786 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 25 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.570 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.490 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.470 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.470 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.420 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.410 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.410 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.380 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.310 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.300 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.290 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.280 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.270 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.240 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.220 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.190 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.110 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.100 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.080 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.060 | Idelalisib | — uncovered |